Boston Family Office LLC Acquires 1,563 Shares of Pfizer Inc. (NYSE:PFE)

Boston Family Office LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,845 shares of the biopharmaceutical company’s stock after acquiring an additional 1,563 shares during the quarter. Boston Family Office LLC’s holdings in Pfizer were worth $1,800,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares during the last quarter. StoneX Group Inc. increased its position in Pfizer by 43.5% in the fourth quarter. StoneX Group Inc. now owns 76,031 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 23,050 shares during the period. Nemes Rush Group LLC increased its position in Pfizer by 8.7% in the fourth quarter. Nemes Rush Group LLC now owns 126,861 shares of the biopharmaceutical company’s stock worth $3,366,000 after purchasing an additional 10,189 shares during the period. Mosaic Financial Group LLC bought a new stake in Pfizer during the 4th quarter worth about $208,000. Finally, Meridian Investment Counsel Inc. lifted its position in Pfizer by 3.4% during the 4th quarter. Meridian Investment Counsel Inc. now owns 65,157 shares of the biopharmaceutical company’s stock valued at $1,729,000 after purchasing an additional 2,137 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $25.36 on Tuesday. The firm’s 50 day moving average price is $26.05 and its two-hundred day moving average price is $26.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $143.80 billion, a P/E ratio of 17.98, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.